

Appl. No. 09/214,277

C¹

--28. A selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time.

29. The selective suppressor of the IgE production claimed in claim 28, wherein a suppression of the IgE production is 10,000 times or more that of the IgG, IgM and/or IgA production.

30. The selective suppressor of the IgE production claimed in claim 28 which does not suppress 50 % or more of the IgG, IgM and/or IgA production even at 10,000 times of the concentration at which 50 % of the IgE production is suppressed as compared with that in the absence of the suppressor.

31. The selective suppressor of the IgE production claimed in claim 28, 29 or 30 which suppresses 90 % or more of the IgE production, as compared with that without administration of the suppressor, at which dosage the suppressor does not suppress or


Appl. No. 09/214,277

weakly suppresses the IgM, IgG and/or IgA production when the suppressor is administered to a mammal sensitized by an allergen.

32. The selective suppressor of the IgE production claimed in claim 28, 29 or 30 which suppresses infiltration of an inflammatory cell to tissue.

33. The selective suppressor of the IgE production claimed in claim 32, wherein the inflammatory cell is an eosinophil and/or a neutrophile.

34. A compound of the formula (I):



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl,

Appl. No. 09/214,277

Sub
m
C1
cont

optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl,

X is -O-, -CH₂-, -NR¹⁴- wherein R¹⁴ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or -S(O)_p- wherein p is an integer of 0 to 2,

Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may optionally be substituted lower alkoxy when X is -CH₂- and may optionally be substituted lower alkoxy carbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is -O- or -NR¹⁴-,


R¹ and R⁴, R¹ and R², R² and R³, R⁴ and R⁵, R⁶ and R⁷, R⁸ and R⁹, R¹⁰ and R¹¹, R¹² and R¹³, R¹¹ and -X-Y, or R¹³ and -X-Y taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR¹⁵ wherein R¹⁵ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted arylsulfonyl and which may optionally be substituted,

Appl. No. 09/214,277

Sub
D'

Q1
count

excluding compounds wherein one or more of R⁶, R⁷, R⁸ and R⁹ are halogen and the others are hydrogen, compounds wherein all of R⁶, R⁷, R⁸ and R⁹ are halogen and compounds wherein all of R²-R¹³ are hydrogen, halogen or cyano, provided that R¹ is not hydrogen, fluorine, optionally substituted lower alkyl or optionally substituted lower alkoxy, all of R², R³, R⁴, R⁵ and R¹² are hydrogen, or R¹³ is not hydrogen or halogen when R⁶, R⁷, R⁸ and R⁹ are all simultaneously hydrogen, and further provided that R¹ is not methyl or acetyloxy, R¹³ is not hydrogen, optionally substituted lower alkoxycarbonyl or optionally substituted carbanoyl, or -X-Y is not methoxy when at least one of R⁶, R⁷, R⁸ and R⁹ is a substituent other than hydrogen, and excluding a compound of the formula (I'):



wherein R^{1'} is hydrogen or hydroxy and R^{13'} is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

35. The compound claimed in claim 34 wherein R¹ is hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl,

Appl. No. 09/214,277

Sub
DI
CI
cont

optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy, lower alkylsulfonyl, formyl, optionally substituted amino, lower alkylsulfinyl, acyloxy, nitro, cyano, optionally substituted sulfamoyl or heterocyclyl,

R^2 is hydrogen, hydroxy, halogen, optionally substituted lower alkyl or optionally substituted lower alkylsulfonyloxy,

R^3 is hydrogen, hydroxy, halogen or optionally substituted lower alkoxy,

R^4 is hydrogen, optionally substituted lower alkyl, halogen, optionally substituted lower alkoxy, nitro or optionally substituted amino,

R^5 is hydrogen, optionally substituted lower alkoxy, lower alkoxycarbonyl or carboxy,

R^6 is hydrogen, halogen, optionally substituted lower alkyl, carboxy, lower alkoxycarbonyl, nitro, formyl, amino or lower alkylsulfonyloxy,

R^7 and R^8 are each independently hydrogen, halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, formyl or optionally substituted amino.

Appl. No. 09/214,277

*cl
cont
Sub
DI*

~~R⁹ is hydrogen, hydroxy, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy, formyl, optionally substituted carbamoyl or optionally substituted amino,~~

~~R¹⁰ is hydrogen or lower alkoxy,~~

~~R¹¹ is hydrogen, halogen, optionally substituted lower alkyl, carboxy, lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy, formyl, nitro or amino,~~

~~R¹² is hydrogen,~~

~~R¹³ is hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted acyloxy, optionally substituted lower alkylsulfonyloxy, formyl, nitro or optionally substituted amino,~~

~~Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl or optionally substituted cycloalkenyl and Y may be optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is -O- or -NR¹⁴-,~~

Appl. No. 09/214,277

and R¹ and R², R¹ and R⁴, R⁸ and R⁹, R¹¹ and -X-Y, or R¹ and -X-Y taken together may form a 5- or 6-membered ring which contains one or more of O or NR¹⁵ wherein R¹⁵ is the same as defined in claim 34 and which may optionally be substituted, pharmaceutically acceptable salt, hydrate or prodrug thereof.

C1
cont 36. The compound, pharmaceutically acceptable salt or hydrate thereof claimed in claim 34 or 35 which has an immunosuppressive effect.

Sub
D2 37. The pharmaceutical composition comprising the compound, pharmaceutically acceptable salt, hydrate or prodrug thereof claimed in claim 34 or 35.


38. An immunosuppressor comprising the compound, pharmaceutically acceptable salt, hydrate or prodrug thereof claimed in claim 34 or 35.

39. An anti-allergic agent comprising the compound, pharmaceutically acceptable salt, hydrate or prodrug thereof claimed in claim 34 or 35.

Appl. No. 09/214,277

40. An immunosuppressor comprising a compound of the formula

(I''):



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl optionally substituted, lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl,

X is $-O-$, $-CH_2-$, $-NR^{14}-$ wherein R^{14} is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or $-S(O)_p-$ wherein p is an integer of 0 to 2,


Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally

Appl. No. 09/214,277

Sub
D3

g1
cont

substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may optionally be substituted lower alkoxy when X is $-\text{CH}_2-$ and may optionally be substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is $-\text{O}-$ or $-\text{NR}^{14}-$, R^1 and R^4 , R^1 and R^2 , R^2 and R^3 , R^4 and R^5 , R^6 and R^7 , R^8 and R^9 , R^{10} and R^{11} , R^{12} and R^{13} , R^{11} and $-\text{X}-\text{Y}$, or R^{13} and $-\text{X}-\text{Y}$ taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR^{15} wherein R^{15} is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or optionally substituted arylsulfonyl and which may optionally be substituted, excluding a compound of the formula (I'):




wherein $\text{R}^{1'}$ is hydrogen or hydroxy and $\text{R}^{13'}$ is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

41. An anti-allergic agent comprising the compound of the formula (I') according to claim 40, pharmaceutically acceptable salt, hydrate or prodrug thereof.


Appl. No. 09/214,277

42. A process for producing a compound of the formula (I) of claim 34 which comprises reacting a compound of the formula (II):



(II)

with a compound of the formula (III):




(III)

wherein, in the formulas (II) and (III), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl,

Appl. No. 09/214,277


X is $-O-$, $-CH_2-$, $NR^{14}-$ wherein R^{14} is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or $-S(O)_p-$ wherein p is an integer of 0 to 2, Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may optionally be substituted lower alkoxy when X is $-CH_2-$ and may optionally be substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is $-O-$ or $-NR^{14}$, R^1 and R^4 , R^1 and R^2 , R^2 and R^3 , R^4 and R^5 , R^6 and R^7 , R^8 and R^9 , R^{10} and R^{11} , R^{12} and R^{13} , R^{11} and $-X-Y$, or R^{13} and $-X-Y$ taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR^{15} wherein R^{15} is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted arylsulfonyl, and which may optionally be substituted, either of A and Z is dihydroxyborane, di(lower)alkoxyborane, di(lower)alkylborane,




Appl. No. 09/214,277

and the other is halogen or $-\text{OSO}_2(\text{C}_q\text{F}_{2q+1})-$ wherein q is an integer of 0 to 4,

or reacting a compound of the formula (II'):




with a compound of the formula (III'):




wherein, in the formulas (II') and (III'), $R^1 - R^{13}$, X and Y are the same as defined above and A and Z are the same as defined in the above formulas (II) and (III).

43. The process for producing the compound of the formula (I) according to claim 42, pharmaceutically acceptable salt or hydrate thereof comprising the reaction of a compound of the formula (IV):




with a compound of the formula (V):

Appl. No. 09/214,277



wherein, in the formulas (IV) and (V), R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl, Z¹ is defined the same as for Z in the formula (II), A¹ and A² are each independently defined the same as for A in the formula (III), and the reactivity of A¹ is higher than or equal to that of A², followed by the reaction with a compound of the formula (VI):




Appl. No. 09/214,277

*C1
cont*


wherein R^{10} - R^{13} , are as defined for R^6 - R^9 above, X is -O-, -CH₂-, NR¹⁴- wherein R¹⁴ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or -S(O)_p- wherein p is an integer of 0 to 2, Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may optionally be substituted lower alkoxy when X is -CH₂- and may optionally be substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is -O- or -NR¹⁴, R¹ and R⁴, R¹ and R², R² and R³, R⁴ and R⁵, R⁶ and R⁷, R⁸ and R⁹, R¹⁰ and R¹¹, R¹² and R¹³, R¹¹ and -X-Y, or R¹³ and -X-Y taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR¹⁵ wherein R¹⁵ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted arylsulfonyl, and which may optionally be substituted, and Z² is the same as Z¹ defined in the above formula (II).

Appl. No. 09/214,277

44. The process for producing the compound of the formula (I) according to claim 42, pharmaceutically acceptable salt or hydrate thereof comprising the reaction of a compound of the formula (IV'):



wherein, R^6 , R^7 , R^8 and R^9 are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl, A^1 and A^2 are each independently defined the same as A in the formula (III), and the reactivity of A^2 is higher than or equal to that of A^1 , with a compound of the formula (VI),




Appl. No. 09/214,277

C1
cont

wherein R^{10} - R^{13} , are as defined for R^6 - R^9 above, X is -O-, -CH₂-, NR¹⁴- wherein R¹⁴ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or -S(O)_p- wherein p is an integer of 0 to 2, Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may optionally be substituted lower alkoxy when X is -CH₂- and may optionally be substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is -O- or -NR¹⁴, R¹ and R⁴, R¹ and R², R² and R³, R⁴ and R⁵, R⁶ and R⁷, R⁸ and R⁹, R¹⁰ and R¹¹, R¹² and R¹³, R¹¹ and -X-Y, or R¹³ and -X-Y taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR¹⁵ wherein R¹⁵ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted arylsulfonyl, and which may optionally be substituted, and Z² is defined the same as Z in formula (II),

followed by the reaction with a compound of the formula (V)


Appl. No. 09/214,277



wherein R^1 - R^5 are as defined for R^6 - R^9 above, Z^1 is defined the same as for Z in the formula (II).

Q1
Cont

45. A compound of the formula (I):



wherein R^1 is hydrogen, halogen, optionally substituted lower alkenyloxy, optionally substituted lower alkylsulfonyloxy, optionally substituted amino or optionally substituted sulfamoyl,

R^2 is hydrogen, halogen or lower alkyl having 1 to 3 carbon atoms,

R^3 is hydrogen or halogen,

R^4 is hydrogen, lower alkyl, lower alkoxy or halogen,

R^5 is hydrogen, lower alkoxy carbonyl or carboxy,

R^6 is hydrogen, lower alkyl or halogen,

Appl. No. 09/214,277

GI
cont
Sub
D4


~~R¹ is hydrogen, lower alkyl or lower alkoxy,
R⁸ is hydrogen, lower alkyl or lower alkoxy,
R⁹ is hydrogen, hydroxy, carboxy, optionally substituted lower
alkyl, optionally substituted lower alkoxy, optionally
substituted lower alkenyl, optionally substituted lower
alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy,
formyl, optionally substituted carbamoyl or optionally
substituted amino,
R¹⁰ is hydrogen,
R¹¹ is hydrogen or halogen,
R¹² is hydrogen,
R¹³ is hydrogen, hydroxy, halogen, carboxy, optionally
substituted lower alkyl, optionally substituted lower alkoxy,
optionally substituted acyloxy, optionally substituted lower
alkylsulfonyloxy, formyl or optionally substituted amino,
X is -O-, -NH-, -NMe- or -SO₂-,
Y is lower alkyl optionally substituted with lower
alkoxycarbonyl, aryl, lower alkylaryl, halogenoaryl, lower
alkoxyaryl, heterocyclyl or acyl; or lower alkenyl optionally
substituted with hydroxy, halogen or aryl,
and R¹ and R⁴ or R⁸ and R⁹ taken together may form a 5- or
6-membered ring which contains one or more of O,~~

Appl. No. 09/214,277

excluding compounds wherein one or more of R^6 , R^7 , R^8 and R^9 are halogen and the others are hydrogen and compounds wherein all of R^2 - R^{13} are hydrogen,

provided that R^1 is not hydrogen or fluorine, all of R^2 , R^3 , R^4 , R^5 and R^{12} are hydrogen, or R^{13} is not hydrogen or halogen when R^6 , R^7 , R^8 and R^9 are simultaneously hydrogen,


and further provided that R^{13} is not hydrogen or -X-Y is not methoxy when at least one of R^6 , R^7 , R^8 and R^9 is a substituent other than hydrogen, and excluding a compound of the formula (I'):



wherein $R^{1'}$ is hydrogen or hydroxy and $R^{13'}$ is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

46. A compound of the formula (I):

Appl. No. 09/214,277



CP
cont
Sub
py

wherein R¹ is hydrogen, hydroxy, halogen, optionally substituted lower alkoxy, optionally substituted alkenyloxy, optionally substituted lower alkylsulfonyloxy, optionally substituted amino or optionally substituted sulfamoyl,

R² is hydrogen, halogen or lower alkyl having 1 to 3 carbon atoms,

R³ is hydrogen or halogen,

R⁴ is hydrogen, lower alkyl, lower alkoxy or halogen,

R⁵ is hydrogen, lower alkoxycarbonyl or carboxy,

R⁶ is hydrogen, lower alkyl or halogen,

R⁷ is hydrogen, lower alkyl or lower alkoxy,

R⁸ is hydrogen, lower alkyl or lower alkoxy,

R⁹ is hydrogen, hydroxy, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy,

Appl. No. 09/214,277

Sub
D4

formyl, optionally substituted carbamoyl or optionally

substituted amino,

R¹⁰ is hydrogen,

R¹¹ is hydrogen or halogen,

R¹² is hydrogen,

R¹³ is hydrogen, hydroxy, halogen, carboxy, optionally

substituted lower alkyl, optionally substituted lower alkoxy,

optionally substituted acyloxy, optionally substituted lower

alkylsulfonyloxy, formyl or optionally substituted amino,

X is -O-, -NH-, -NMe- or -SO₂-,

Y is lower alkyl optionally substituted with aryl; or lower
alkenyl,


and R¹ and R⁴ or R⁸ and R⁹ taken together may form a 5- or
6-membered ring which contains one or more of O,

excluding compounds wherein one or more of R⁶, R⁷, R⁸ and R⁹ are
halogen and the others are hydrogen and compounds wherein all of
R²-R¹³ are hydrogen, provided that R¹ is not hydrogen, fluorine or
optionally substituted lower alkoxy, all of R², R³, R⁴, R⁵ and R¹²
are hydrogen, or R¹³ is not hydrogen or halogen when R⁶, R⁷, R⁸
and R⁹ are all simultaneously hydrogen, and further provided that
R¹³ is not hydrogen or -X-Y is not methoxy when at least one of

Appl. No. 09/214,277

Sub
D4

R^6 , R^7 , R^8 and R^9 is a substituent other than hydrogen, and excluding a compound of the formula (I'):




wherein $R^{1'}$ is hydrogen or hydroxy and $R^{13'}$ is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

47. The compound, pharmaceutically acceptable salt or hydrate thereof claimed in claim 46 wherein Y is methylbutenyl.

48. The compound, pharmaceutically acceptable salt or hydrate thereof claimed in claim 46 wherein -X-Y is $-OCH_2CH=CMe_2$, or $-OCH_2C_6H_5$.

Sub
D5

49. A compound of the formula (I):



Appl. No. 09/214,277

Sub
DS
Q1
cont

wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}$ and R^{13} are each independently hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkenyloxy, optionally substituted lower alkylthio, optionally substituted lower alkoxycarbonyl, optionally substituted acyloxy, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylsulfonyloxy, optionally substituted lower alkylsulfinyl, nitro, cyano, formyl, optionally substituted amino, optionally substituted carbamoyl, optionally substituted sulfamoyl or optionally substituted heterocyclyl,

X is $-O-$, $-CH_2-$, $-NR^{14}-$ wherein R^{14} is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or acetyl, or $-S(O)_p-$ wherein p is an integer of 0 to 2,


Y is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl or optionally substituted heterocyclyl, and Y may be optionally substituted lower alkoxy when X is $-CH_2-$ and may be optionally

Appl. No. 09/214,277

Sub
PS
C/
cont

substituted lower alkoxy carbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is -O- or -NR¹⁴-, R¹ and R⁴, R¹ and R², R² and R³, R⁴ and R⁵, R⁶ and R⁷, R⁸ and R⁹, R¹⁰ and R¹¹, R¹² and R¹³, R¹¹ and -X-Y, or R¹³ and -X-Y taken together may form a 5- or 6-membered ring which may contain one or more of O, S or NR¹⁵ wherein R¹⁵ is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted arylsulfonyl and which may optionally be substituted, excluding compounds wherein one or more of R⁶, R⁷, R⁸ and R⁹ are halogen and the others are hydrogen, compounds wherein all of R⁶, R⁷, R⁸ and R⁹ are halogen and compounds wherein all of R²-R¹³ are hydrogen, halogen or cyano, provided that R¹ is not hydrogen, fluorine, optionally substituted lower alkyl or optionally substituted lower alkoxy, all of R², R³, R⁴, R⁵ and R¹² are hydrogen, and R¹³ is not hydrogen or halogen when R⁶, R⁷, R⁸ and R⁹ are all simultaneously hydrogen, and further provided that R¹ is not methyl or acetyloxy, R¹³ is not hydrogen, optionally substituted lower alkoxy carbonyl or optionally substituted carbamoyl, and -X-Y is not methoxy when at least one of R⁶, R⁷, R⁸ and R⁹ is a substituent other than hydrogen, and excluding a compound of the formula (I'):

Appl. No. 09/214,277



CI
cont

wherein $R^{1'}$ is hydrogen or hydroxy and $R^{13'}$ is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

50. The selective suppressor of the IgE production claimed in claim 31 which suppresses infiltration of an inflammatory cell to tissue.

51. The selective suppressor of the IgE production claimed in claim 50 wherein the inflammatory cell is an eosinophil and/or a netrophile.


Sub
OK

52. A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt, hydrate or prodrug thereof claimed in claims 45, 46, 47, 48 or 49.


53. A process for producing a compound of the formula (I) according to claims 45, 46, 47, 48 or 49, pharmaceutically

Appl. No. 09/214,277

acceptable salt or hydrate thereof comprising reacting a compound of the formula (IV)



with a compound of the formula (V):



wherein, in the formulas (IV) and (V),

R¹ is hydrogen, halogen, optionally substituted lower alkenyloxy, optionally substituted lower alkylsulfonyloxy, optionally substituted amino or optionally substituted sulfamoyl,

R² is hydrogen, halogen or lower alkyl having 1 to 3 carbon atoms,

R³ is hydrogen or halogen,

R⁴ is hydrogen, lower alkyl, lower alkoxy or halogen,

R⁵ is hydrogen, lower alkoxycarbonyl or carboxy,

R⁶ is hydrogen, lower alkyl or halogen,

R⁷ is hydrogen, lower alkyl or lower alkoxy,


R⁸ is hydrogen, lower alkyl or lower alkoxy,

Appl. No. 09/214,277

Cl
cont

R^9 is hydrogen, hydroxy, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy, formyl, optionally substituted carbamoyl or optionally substituted amino,

Z^1 , A^1 and A^2 are each independently dihydroxyborane, di(lower)alkoxyborane, di(lower)alkylborane,



and the other is halogen or $-\text{OSO}_2(\text{C}_q\text{F}_{2q+1})-$ wherein q is an integer of 0 to 4, and the reactivity of A^1 is higher than or equal to that of A^2 ,

followed by the reaction with a compound of the formula (VI):



wherein R^{10} is hydrogen,

R^{11} is hydrogen or halogen,


R^{12} is hydrogen,

Appl. No. 09/214,277

R^{13} is hydrogen, hydroxy, halogen, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted acyloxy, optionally substituted lower alkylsulfonyloxy, formyl or optionally substituted amino,

X is -O-, -NH-, -NMe- or -SO₂-,


Y is lower alkyl optionally substituted with lower alkoxycarbonyl, aryl, lower alkylaryl, halogenoaryl, lower alkoxyaryl, heterocyclyl or acyl; or lower alkenyl optionally substituted with hydroxy, halogen or aryl, and excluding compounds wherein one or more of R^6 , R^7 , R^8 and R^9 are halogen and the others are hydrogen and compounds wherein all of R^2 - R^{13} are hydrogen, provided that R^1 is not hydrogen or fluorine, all of R^2 , R^3 , R^4 , R^5 and R^{12} are hydrogen, or R^{13} is not hydrogen or halogen when R^6 , R^7 , R^8 and R^9 are simultaneously hydrogen, and further provided that R^{13} is not hydrogen or -X-Y is not methoxy when at least one of R^6 , R^7 , R^8 and R^9 is a substituent other than hydrogen, and excluding a product compound of the formula (I'):



Appl. No. 09/214,277

wherein $R^{1'}$, is hydrogen or hydroxy and $R^{13'}$ is hydroxy or methoxy, pharmaceutically acceptable salt, hydrate or prodrug thereof.

CI
Cont
54. A process for producing a compound of the formula (I), according to claims 45, 46, 47, 48 or 49 pharmaceutically acceptable salt or hydrate thereof comprising reacting a compound of the formula (IV')



wherein

R^6 is hydrogen, lower alkyl or halogen,

R^7 is hydrogen, lower alkyl or lower alkoxy,


R^8 is hydrogen, lower alkyl or lower alkoxy,

R^9 is hydrogen, hydroxy, carboxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyloxy,

Appl. No. 09/214,277


formyl, optionally substituted carbamoyl or optionally substituted amino,

wherein A^1 and A^2 are each independently dihydroxyborane, di(lower)alkoxyborane, di(lower)alkylborane,



and the other is halogen or $-\text{OSO}_2(\text{C}_q\text{F}_{2q+1})-$ wherein q is an integer of 0 to 4, and the reactivity of A^1 is higher than or equal to that of A^2 , and the reactivity of A^1 is higher than or equal to that of A^2 ,

with a compound of the formula (VI)




wherein R^{10} - R^{13} are as defined for R^6 - R^9 above,

X is $-\text{O}-$, $-\text{NH}-$, $-\text{NMe}-$ or $-\text{SO}_2-$,

Y is lower alkyl optionally substituted with lower alkoxy, carbonyl, aryl, lower alkylaryl, halogenoaryl, lower alkoxyaryl, heterocyclyl or acyl; or lower alkenyl optionally substituted with hydroxy, halogen or aryl,


Appl. No. 09/214,277

wherein Z^2 is dihydroxyborane, di(lower)alkoxyborane, di(lower)alkylborane,



and the other is halogen or $-\text{OSO}_2(\text{C}_q\text{F}_{2q+1})-$ wherein q is an integer of 0 to 4,

followed by the reaction with a compound of the formula (V)



wherein R^1 - R^5 are as defined for R^6 - R^9 above, Z^1 is defined the same as for Z^2 above,

and excluding compounds wherein one or more of R^6 , R^7 , R^8 and R^9 are halogen and the others are hydrogen and compounds wherein all of R^2 - R^{13} are hydrogen,

provided that R^1 is not hydrogen or fluorine, all of R^2 , R^3 , R^4 , R^5 and R^{12} are hydrogen, or R^{13} is not hydrogen or halogen when R^6 , R^7 , R^8 and R^9 are simultaneously hydrogen,

and further provided that R^{13} is not hydrogen or $-\text{X}-\text{Y}$ is not methoxy when at least one of R^6 , R^7 , R^8 and R^9 is a substituent